List of Excipients in Branded Drug PREVPAC

Excipient Strategy and Commercial Opportunities for PREVPAC (lansoprazole + amoxicillin + clarithromycin)

Last updated: June 30, 2026

Executive summary

• PREVPAC (lansoprazole 30 mg + amoxicillin 1 g + clarithromycin 500 mg; metronidazole-free H. pylori “triple therapy” pack) is positioned around a fixed-dose pack convenience model rather than a differentiated single-molecule product.
• Commercial opportunity exists in (1) higher-absorbing, patient-tolerable formulations that improve adherence and reduce pill burden within the pack construct, (2) stability- and process-robust excipient systems that lower manufacturing cost and improve shelf life, and (3) “right-fit” generic and authorized-generic strategies that avoid design-around risk when replicating the specific excipient and physical-chemistry profile.
• The dominant competitive lever is likely to be pack-level performance and manufacturability: dissolution behavior of lansoprazole, moisture/heat stability of clarithromycin, and controlled release and flow properties for immediate-release antibiotic dosing.

What excipients are in PREVPAC and how do they drive stability, dissolution, and tolerability?

Direct answer: PREVPAC is a fixed-dose combination pack. Its excipient strategy is defined by the excipient compositions of each component dosage form (lansoprazole delayed-release capsules/tablets and immediate-release antibiotic tablets/capsules, depending on marketed strength and presentation).

How do excipients change lansoprazole performance in a triple-therapy pack?

Lansoprazole is a proton pump inhibitor that is sensitive to chemical degradation pathways influenced by moisture and temperature history. Excipient selection typically targets:

• Moisture barrier performance (lower water activity exposure across the marketed shelf life)
• Acid resistance and protection of delayed-release functionality
• Dissolution timing that aligns with pH transitions in the GI tract

Common excipient “functions” to watch in PPIs (by role, not brand-specific labeling):

• Film formers and enteric polymers (for delayed release)
• Fillers/diluents that control compaction and porosity
• Lubricants (to manage tablet tensile strength and disintegration)
• Desiccant strategy at pack level (secondary packaging and headspace control)

How do excipients affect clarithromycin stability?

Clarithromycin has known solid-state and stability sensitivities that can be exacerbated by:

• Elevated humidity exposure
• High-temperature excursions during processing and distribution
• Interactions with acidic microenvironments created by adjacent components

Excipient strategy typically targets:

• Water absorption control
• Solid-state preservation (polymorph and amorphous fraction control in granules/tablets)
• Thermal and photostability management

How do excipients affect amoxicillin release and microbiological performance?

Amoxicillin is less chemically fragile than PPIs but is sensitive to:

• Water uptake in hygroscopic formulations
• Mechanical stress during manufacturing
• Potential interactions within fixed-dose packs if packaging does not isolate microenvironments

Excipient strategy typically targets:

• Rapid wetting and disintegration
• Consistent dose delivery within batch-to-batch variability constraints
• Flowability for high-speed tableting/capsule filling

What excipient and manufacturing details matter for IP and design-around risk?

From a commercial IP standpoint, excipient selection can matter in three ways:

1. Bioequivalence sensitivity: if the solid-state form and release profile shift, the product may require additional bridging studies.
2. Stability-driven shelf-life: stability differences can force shorter expiration dating and increase inventory carrying costs.
3. Method-of-manufacture dependence: process parameters tied to excipient properties can become hard to replicate without similar formulation and equipment controls.

How should you structure an excipient strategy for PREVPAC-like H. pylori triple therapy products?

Direct answer: Build an excipient system around solid-state robustness at pack level: moisture control, chemical incompatibility mitigation, and release-profile matching for lansoprazole delayed release and immediate antibiotic kinetics.

What “system-level” excipient architecture supports pack robustness?

A practical excipient roadmap is to treat each component dosage form as its own stability system, then ensure that pack configuration limits cross-component influence:

• Primary packaging selection per component (to limit humidity migration)
• Headspace control in bottles/pouches (desiccant placement and barrier films)
• Compatible excipient boundaries to reduce reactive microenvironments

Which excipient functions typically create differentiable performance?

High-leverage excipient functions for fixed-dose packs:

• Moisture barrier excipients and water-activity reducers (within dosage form)
• Enteric protection systems for the PPI component
• Granulation and binder systems that improve content uniformity and mechanical integrity
• Lubricants that preserve disintegration and dissolution kinetics after compression

What excipient choices increase manufacturability and reduce cost?

Cost and scale depend on:

• Lower loss-on-drying time and improved drying efficiency for granules
• Better flow for direct compression or reduced granulation time
• Excipient availability and supply continuity
• Reduced batch rejection rates tied to tablet hardness, friability, and dissolution drift

What patient-centric levers can excipients enable?

Even without changing active ingredient dosing, excipients can enable:

• Reduced tablet/capsule size by improving compressibility and density
• Less gritty mouthfeel for dispersible or swallow-friendly designs (if a platform is adopted)
• Better tolerance through more predictable release and reduced local irritation (indirectly linked to excipient microenvironment and release kinetics)

What patents protect excipient systems for PREVPAC-like combinations, and where is the IP boundary?

Direct answer: Patent protection around excipients is usually framed as formulation compositions, solid-state forms, or method-of-manufacture steps rather than excipient “ingredients” alone. The most defensible IP tends to link excipient systems to dissolution, stability, and manufacturability outcomes.

How to map likely formulation IP categories relevant to PREVPAC

For combination triple therapies similar to PREVPAC, IP typically falls into:

• Delayed-release PPI enteric formulation patents
• Antibiotic tablet or capsule composition patents
• Stability-enhancing excipient combinations (moisture management, protective coatings)
• Granulation/binding/lubrication and process parameter claims
• Pack-level or regimen packaging patents (if claimed)

Which excipient-related claim themes tend to be strong?

The claims most likely to be litigated or to block competitors are those that:

• Specify an excipient ratio or defined material property range (particle size, viscosity grade, polymer molecular weight)
• Tie excipient choice to measured dissolution curves, water uptake, or shelf-life stability
• Include manufacturing steps (granulation endpoint, mixing times, drying conditions)

When does PREVPAC lose exclusivity, and does excipient strategy change that timeline?

Direct answer: Exclusivity timelines for PREVPAC are driven primarily by patent estate and regulatory exclusivity tied to the fixed-dose combination, not by excipient “strategy” alone.

How Orange Book status changes competitive timing

For commercial planning, the relevant question is whether the innovator product is protected by:

• Composition-of-matter patents for any component
• Combination and formulation patents
• Method-of-use patents
• Method-of-manufacture patents that can block generic design-around

Excipient improvements often influence whether a generic can match the innovator release and stability profile sufficiently for fast regulatory approval, but they do not typically shift patent expiration dates.

Where excipient strategy influences launch risk even after patent expiry

Even after expiry, launch risk depends on:

• Patent whitespace that still covers formulation improvements
• Litigation posture on formulation/process claims
• Practical bioequivalence feasibility if excipients materially alter dissolution timing

What is the Orange Book status of PREVPAC, and how does it affect excipient choices for generics?

Direct answer: PREVPAC’s regulatory status and listed patents control what a generic or authorized distributor must clear. Excipient selection is part of the pathway to bioequivalence, but the gating item is the patent list and any active litigation.

What to look for in Orange Book entries

For excipient-aware competition, prioritize:

• Patent types covering formulation and manufacturing
• Patents that reference specific dosage forms for each component
• Any listed patents that are compatible with a stability or delayed-release mechanism

What generic entry risks exist for PREVPAC based on excipient and manufacturing barriers?

Direct answer: The main generic entry risks are practical: excipient-driven release profile mismatch, moisture stability shortfalls that reduce shelf life, and process replication difficulty that can trigger additional studies.

How excipient mismatch can create bioequivalence problems

Even for a combination product, bioequivalence is sensitive to:

• PPI delayed-release integrity
• Antibiotic dissolution/absorption timing
• Variability introduced by different binders, lubricants, disintegrants, and coatings

How stability-driven shelf-life issues can delay market access

If a generic replicates the actives and strength but selects:

• Less robust moisture barrier systems
• Different enteric coating excipients
• Different granulation binder that retains more water …it can face stability failures that force reformulation and delay launch timelines.

Litigation patterns to anticipate in formulation-heavy triple therapies

Formulation and method claims are often litigated because competitors can attempt design-around using different excipients but still run into claim coverage if the claimed ranges or functional outcomes overlap.

What is the commercial opportunity in excipient-driven differentiation for H. pylori triple therapy packs?

Direct answer: Excipient-driven differentiation is most viable in three commercial lanes: improved tolerability/adherence, manufacturing cost reduction, and supply-chain robustness.

Lane 1: Adherence and tolerability improvements through pill ergonomics

• Excipient selection can reduce overall tablet/capsule burden without changing dose strength, by improving compressibility and content uniformity.
• This is a route to differentiation that can support payer conversations even without major clinical re-statements.

Lane 2: Cost and COGS downshift through manufacturability

• Better flow and lower granulation losses reduce cost.
• Excipient standardization across component SKUs can reduce variability and reduce line-change time.

Lane 3: Shelf-life extension and distribution resilience

• Moisture-barrier systems and compatible packaging reduce the failure rate under real-world temperature/humidity swings.
• Longer shelf life reduces expired product risk and increases inventory turns.

Packaging as an excipient-adjacent lever

Pack-level desiccant and barrier films can function as a stability “system” comparable to an excipient strategy, enabling:

• More forgiving secondary handling
• Improved shelf-life and reduced reformulation pressure

How does PREVPAC compare with other H. pylori regimens on formulation and excipient opportunities?

Direct answer: In H. pylori treatment, multiple regimens exist (different combinations and durations). PREVPAC’s opportunity space is driven by its fixed-dose triple pack model. Competitors can win by:

• Changing regimen timing (non-PPI alternatives, b.i.d dosing structures)
• Changing delivery system design to reduce pill burden
• Improving stability and reducing manufacturing costs

What delivery platform changes create the biggest excipient advantage?

In general, the highest-value excipient opportunities are in:

• Enteric and protective coating systems for PPIs
• Compression and granulation systems that stabilize antibiotic release
• Pack-level moisture management tied to real-world distribution conditions

Key Takeaways

• PREVPAC’s commercial positioning depends on pack-level performance: lansoprazole delayed release reliability and moisture/heat stability for antibiotics.
• Excipient strategy that improves moisture control, release profile matching, and manufacturability creates tangible market value even when active ingredients and dosing are fixed.
• Generic and authorized-generic competition is constrained by Orange Book patent lists and by the practical feasibility of excipient-driven bioequivalence and stability.
• The most defensible differentiation routes are adherence (pill ergonomics), COGS reduction (robust manufacturing), and shelf-life extension (packaging and moisture systems).

FAQs

1) Which excipient functions most often drive bioequivalence risk in PPI + antibiotic fixed-dose combinations?
Enteric-coating polymer systems, disintegrants and lubricants that change disintegration and dissolution, and moisture-handling excipients that affect solid-state integrity.

2) Can excipient changes extend PREVPAC shelf life without altering the actives and dosing?
Yes when the improvement targets water uptake and chemical stability, but reformulation may trigger additional development and regulatory review if release or stability specifications move.

3) What formulation attributes should a generic supplier prioritize to avoid stability-driven delays for PREVPAC-like products?
Water activity control, coating integrity for delayed release, granulation endpoint consistency, and barrier packaging with effective desiccant strategy.

4) Does excipient strategy matter for Paragraph IV challenges in fixed-dose combinations?
It can, because formulation differences can intersect with formulation/process claims and affect bridging study outcomes that influence litigation posture and settlement terms.

5) Where do manufacturing scale-up constraints intersect with excipient selection for combination packs?
Drying behavior, flow properties for high-speed production, compression performance (hardness/friability), and stability under process heat and humidity excursions.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Application Integrity Policy and Biopharmaceutics/Bioequivalence guidance documents. U.S. Food and Drug Administration.
3. USP. General Chapters on Drug Substances, Dosage Forms, and Dissolution/Disintegration. U.S. Pharmacopeia.